All News
Filter News
Found 355 articles
-
FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections
12/21/2021
In advance of the shareholder vote for the business combination between FS Development Corp. II (NASDAQ: FSII) and Pardes Biosciences, Inc. (“Pardes”), the CEOs of both companies are sharing their thoughts on the COVID-19 public health emergency and how they expect the combined company to play an important role in addressing one of the biggest health crises of our time.
-
Tasso Secures $100M in Series B Financing
12/16/2021
Tasso, Inc., a leader in clinical-grade blood collection technology, announced that it has completed an oversubscribed $100 million Series B financing round, bringing the total funding to date to $131 million.
-
Mythic Therapeutics has roared out of the gate with a $103 million Series B financing round that will support “safer and smarter” next generation of antibody-drug conjugates (ADCs).
-
Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma
12/15/2021
Ivantis Inc., developer of the novel Hydrus® Microstent, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent cataract surgery.
-
Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing
12/15/2021
Mythic Therapeutics today announced its launch to develop smarter and safer antibody-drug conjugates (ADCs) with an oversubscribed Series B financing round of $103 million.
-
Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from its pipeline and its discovery platform.
-
Odyssey Therapeutics Announces $218 Million Series A Financing to Advance Next Generation Inflammation and Oncology Medicines
12/7/2021
Odyssey Therapeutics today announced the completion of an oversubscribed $218 million Series A financing led by OrbiMed Advisors and co-led by SR One Capital Management with participation from Foresite Capital, Woodline Partners LP, Logos Capital, HBM Healthcare Investments, Colt Ventures, Creacion Ventures, and other institutional investors.
-
Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer
12/6/2021
Biohaven Pharmaceutical Holding Company Ltd. today announced that the Board of Directors unanimously elected Vlad Coric, MD to the role of Chairman of the Board of Directors following the retirement of Declan Doogan, MD, effective immediately.
-
Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data
11/15/2021
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
bit.bio Raises in Excess of $100 Million in First Close of Series B Financing
11/5/2021
Human cell coding company bit.bio announces the first close of their Series B financing of $103 million.
-
Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen
11/1/2021
Venatorx Pharmaceuticals announced today that it has entered into a Research Collaboration and License Agreement with Roche to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (“PBPs”)
-
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
10/26/2021
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced a new partnership to develop in vivo gene-editing therapies for two genetic diseases using Mammoth’s next-generation CRISPR systems.
-
Esker Therapeutics tapped Martin Babler to helm the company after founding CEO June Lee has stepped away to pursue other opportunities.
-
Esker Therapeutics Announces Management and Research Team Additions to Accelerate Advancement of Precision Immunology Therapies
9/23/2021
Esker Therapeutics today announced that Martin Babler has joined the company as president, chief executive officer and chairman of the board of directors.
-
Pardes Bioscience Announces Issuance of Its First U.S. PatentThe patent provides coverage for compounds that target the main protease of the SARS-CoV-2 virus
9/21/2021
Pardes Biosciences, Inc., a clinical--stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued a new patent No. 11,124,497 (the “’497 patent”), strengthening the Company’s intellectual property position for the Company’s antiviral drug development program.
-
Mammoth will use the funds to build and broaden its stable of next-generation CRISPR products to detect and cure various diseases.
-
Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnostics
9/9/2021
Mammoth Biosciences, the biotech company leveraging the diversity of life to build the next generation of CRISPR products to cure and detect disease, today announced it has secured $195 million in financing, joining the select ranks of “unicorn” startups with a valuation of more than $1 billion.
-
Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections
8/26/2021
Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the virus that causes COVID-19.
-
Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer
8/17/2021
Remix Therapeutics today announced that Peter Smith , PhD, Co-Founder, President and Chief Scientific Officer of Remix, has been appointed President and Chief Executive Officer.